About Contact Us Careers
Sign In

Psychedelic Drugs Market - Top Companies and Manufacturers

  • Report ID: 4153
  • Published Date: Nov 08, 2024
  • Report Format: PDF, PPT

Companies Dominating the Psychedelic Drugs Landscape

    • Compass Pathways Plc.
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • Mind Medicine Inc.
    • Jazz Pharmaceuticals plc
    • Johnson & Johnson Pte. Ltd.
    • Hikma Pharmaceuticals PLC
    • Thoughtful Brands Inc.
    • Pfizer Inc.
    • F. Hoffmann-La Roche AG
    • Avadel Pharmaceuticals plc
    • NRx Pharmaceuricals, Inc.
Browse Key Market Insights with Data Illustration:

In the News

  • Compass Pathways Plc. a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announced that the American Medical Association (AMA) has approved a Current Procedural Terminology (CPT) III code for psychedelic therapies. The expected release of the full details of the code by the AMA is in July 2023 and the code will go into effect when it is published on January 1, 2024.
  • Mind Medicine Inc., a clinical-stage biopharmaceutical company developing novel products to treat brain health disorders, announced that its collaborators at the University Hospital Basel (UHB) and the University Hospital of Psychiatry, have released positive topline data from an investigator-initiated trial (double-blinded) evaluating lysergide in the treatment of Major Depressive Disorder (MDD)

Author Credits:  Radhika Pawar


  • Report ID: 4153
  • Published Date: Nov 08, 2024
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

In the year 2025, the industry size of psychedelic drugs is assessed at USD 21.86 billion.

The psychedelic drugs market size was over USD 19.84 billion in 2024 and is projected to reach USD 93.88 billion by 2037, witnessing around 12.7% CAGR during the forecast period i.e., between 2025-2037. The market growth can be attributed to growing prevalence of mental health disorders across the globe.

North America industry is likely to dominate majority revenue share of 40% by 2037, due to rising government initiatives to spread awareness among people regarding mental health conditions in the region.

The major players in the market include Compass Pathways Plc., Mind Medicine Inc., Jazz Pharmaceuticals plc, Johnson & Johnson Pte. Ltd., Hikma Pharmaceuticals PLC, Thoughtful Brands Inc., Pfizer Inc., F. Hoffmann-La Roche AG, Avadel Pharmaceuticals plc, NRx Pharmaceuricals, Inc.
Inquiry Before Buying Request Free Sample

Copyright © 2024 Research Nester. All Rights Reserved

logo
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying
Inquiry Before Buying Request Free Sample